Evidence map›Paper›PMID 33903997›Full record

ArticleAIDS and behavior2021

Substance use, Unlike Dolutegravir, is Associated with Mood Symptoms in People Living with HIV.

Lisa Van de Wijer, Wouter van der Heijden, Mike van Verseveld, Mihai Netea, Quirijn de Mast, Arnt Schellekens, André van der Ven

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in AIDS and behavior, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 60% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Lisa Van de WijerDepartment of Internal Medicine, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands. l.vandewijer@radboudumc.nl.ORCID http://orcid.org/0000-0003-2126-6513
Wouter van der HeijdenDepartment of Internal Medicine, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.
Mike van VerseveldDepartment of Psychiatry, Radboud University Medical Center, Nijmegen, The Netherlands.
Mihai NeteaDepartment of Internal Medicine, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.
Quirijn de MastDepartment of Internal Medicine, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.
Arnt SchellekensNijmegen Institute for Scientist Practitioners in Addiction, Nijmegen, The Netherlands.
André van der VenDepartment of Internal Medicine, Radboud University Medical Center, PO Box 9101, 6500 HB, Nijmegen, The Netherlands.
Radboud University Nijmegen · NL

Funding

Aidsfonds P-29001
6 · The paper itself

Abstract

Contradictory data have been reported concerning neuropsychiatric side effects of the first-line antiretroviral drug dolutegravir, which may be partly due to lack of control groups or psychiatric assessment tools. Using validated self-report questionnaires, we compared mood and anxiety (DASS-42), impulsivity (BIS-11), and substance use (MATE-Q) between dolutegravir-treated and dolutegravir-naive people living with HIV (PLHIV). We analyzed 194, mostly male, PLHIV on long-term treatment of whom 82/194 (42.3%) used dolutegravir for a median (IQR) of 280 (258) days. Overall, 51/194 (26.3%) participants reported DASS-42 scores above the normal cut-off, 27/194 (13.5%) were classified as highly impulsive, and 58/194 (29.9%) regularly used recreational drugs. Regular substance use was positively associated with depression (p = 0.012) and stress scores (p = 0.045). We observed no differences between dolutegravir-treated and dolutegravir-naive PLHIV. Our data show that depressed and anxious moods and impulsivity are common in PLHIV and associate with substance use and not with dolutegravir use.

Indexed as

HIV InfectionsSubstance-Related DisordersDolutegravirFemaleHeterocyclic Compounds, 3-RingHumansMaleOxazinesPiperazinesPyridonesDolutegravirHeterocyclic Compounds, 3-RingOxazinesPiperazinesPyridonesAnti-retroviral agentsCentral nervous systemDepressionDolutegravirImpulsive behaviorSide effects

Identifiers

PMID33903997
PMCPMC8602138
OpenAlexW3159581628

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.